Azilect

Type: Product

Name: Azilect

First reported May 02 2013 - Updated May 03 2013 - 3 reports

Generics hurt Teva sales but Copaxone keeps rising

Teva Pharmaceutical Industries has posted a 26.7% decline in net income to $630 million for the first quarter, hit by lower sales of its generics in the USA.Total sales fell 4% to $4.90 billion, while turnover fell 11% in the USA to $2.44 billion, hit ... [Published Pharma Times - May 03 2013]

Entities: Teva Pharmaceutical Industries Ltd, Copaxone, Lipitor, Azilect, Modafinil

First reported May 02 2013 - Updated May 03 2013 - 1 reports

Teva Q1 Profit Down - Quick Facts

Teva Pharmaceutical Industries Limited (TEVA: Quote) reported that its first-quarter net income attributable to the company decreased to $630 million or $0.74 per share, from $859 million or $0.97 per share in the same quarter last year.The company had ... [Published RTTNews.com - May 02 2013]

Entities: Teva Pharmaceutical Industries Ltd, Treanda, Azilect, Modafinil, Copaxone

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Teva Settles Patent Dispute With Orchid Pharma

Israeli drugmaker Teva has settled its patent dispute with India’s Orchid over the Parkinson’s drug Azilect. ... [Published FDA News - May 03 2013]

Entities: Orchidaceae, Patent, Azilect

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Lundbeck confident but cautious as earnings soar

Lundbeck has posted a strong set of financials for the first quarter but has stuck to its earnings guidance for the full year, due to increased generic competition and launch costs.Revenues rose 21% to 4.57 billion kroner (about $807.4 million), while ... [Published Pharma Times - May 02 2013]

Entities: Ebixa, Antidepressant, Clobazam, Xenazine, Vortioxetine

First reported May 01 2013 - Updated May 02 2013 - 3 reports

Orchid Pharma, Teva Agree To Settle U.S. Suit Over Parkinson's Drug

Home » Blogs » Related Biotechnology, Pharmaceutical and Healthcare NewsIndia's Orchid Chemicals & Pharmaceuticals and Teva Pharmaceutical Industries have agreed to drop their suit and counterclaim in a U.S. court over the Israel-based firm's Azilect ... [Published BioPortfolio - May 02 2013]

Entities: Teva Pharmaceutical Industries Ltd, Orchidaceae, Drugs, United States

First reported Mar 20 2013 - Updated Mar 20 2013 - 2 reports

4 Healthcare Stock Stories Prescribed for Investors

Biogen IDEC ( NASDAQ:BIIB ): Current price $177.31 On Wednesday, Biogen announced the positive, full first-year results from its two-year pivotal Phase 3 ADVANCE study of Plegridy (peginterferon beta-1a), its investigational candidate for relapsing-remitting ... [Published Wall St. Cheat Sheet - Mar 20 2013]

Entities: Azilect, Placebo, Merrion Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd

First reported Feb 10 2013 - Updated Feb 10 2013 - 1 reports

Teva Pharmaceutical Industries Ltd

Teva And Pfizer: 2 Solid Pharmaceutical Companies For Healthcare Portfolio

ByNick Chiu: In this article, Teva Pharmaceutical Industries Ltd. and Pfizer Inc. will be analyzed for their recent developments in this article. A quick fundamental and technical analysis will also be reviewed for both stocks. Teva Pharmaceutical ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 10 2013]

Entities: Teva Pharmaceutical Industries Ltd, Pfizer Inc, Portfolio

Quotes

"During the quarter, we were pleased by the overall performance of our specialty products and results of our OTC joint venture. Our generic operations, which are a core component of our business, performed in line with our expectations and were particularly strong in Western and Eastern Europe" President and CEO Jeremy Levin said

Teva First Quarter Results Top Estimates [Published RTTNews.com - May 02 2013]

Chief executive Ulf Wiinberg said Lundbeck's performance in the quarter "brings us a long way in delivering on our expectations for the year, however there is also reason to be cautious as we will see increased generic pressure on Ebixa and increased launch costs throughout the year" . The company will be rolling out the next-generation antidepressant Brintellix (vortioxetine), its once-monthly version of Abilify (aripiprazole) for...

Lundbeck confident but cautious as earnings soar [Published Pharma Times - May 02 2013]

More From BioPortfolio on "Orchid Pharma, Teva Agree To Settle U S Suit Over Parkinson's Drug"

Orchid Pharma, Teva Agree To Settle U.S. Suit Over Parkinson's Drug [Published BioPortfolio - May 02 2013]

Confirming the settlement with Teva on the Parkinson's drug, Orchid Chemicals' spokesperson Ch. Ram, however said, "The details on the compromise deal with regard to the compromise amount from Teva and the terms of product launch are still awaited."

Teva settles patent dispute with Orchid Pharma [Published Economic Times - May 01 2013]

More Content

sort by: Date \| Relevance
Teva Beats on Earnings, Revenues Zacks [Published Yahoo! Finance - May 06 2013]
Generics hurt Teva sales but Copaxone keeps rising [Published Pharma Times - May 03 2013]
Teva Settles Patent Dispute With Orchid Pharma [Published FDA News - May 03 2013]
Teva Pharmaceutical's CEO Discusses Q1 2013 Res... [Published Seeking Alpha - May 02 2013]
Teva First Quarter Results Top Estimates [Published RTTNews.com - May 02 2013]
Lundbeck confident but cautious as earnings soar [Published Pharma Times - May 02 2013]
Teva Q1 Profit Down - Quick Facts [Published RTTNews.com - May 02 2013]
Orchid Pharma, Teva Agree To Settle U.S. Suit O... [Published BioPortfolio - May 02 2013]
Orchid Pharma, Teva Agree To Settle U.S. Suit O... [Published The Rose Sheet - May 02 2013]
Teva settles patent dispute with Orchid Pharma [Published Economic Times - May 01 2013]
Teva Pharmaceutical Industries Limited (TEVA) -... [Published TransWorldNews - Apr 22 2013]
H. Lundbeck AS (LUN) - Financial and Strategic ... [Published TransWorldNews - Apr 18 2013]
4 Healthcare Stock Stories Prescribed for Inves... [Published Wall St. Cheat Sheet - Mar 20 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Conoco... [Published Proactiveinvestors United Kingdom RSS feed - Mar 20 2013]
NEW DATA SHOW AZILECT® (RASAGILINE TABLETS) PRO... [Published GlobeNewswire: Acquisitions News - Mar 20 2013]
New Data Show Azilect® (rasagiline tablets) Pro... [Published Yahoo! Finance - Mar 20 2013]
New Data Show Azilect® (rasagiline tablets) Pro... [Published Business Wire Science: Science News - Mar 20 2013]
New Data Show Azilect® (rasagiline tablets) Pro... [Published Business Wire Health News - Mar 20 2013]
Teva to Present New Research on CNS Product Por... [Published Business Wire Health News - Mar 14 2013]
Teva And Pfizer: 2 Solid Pharmaceutical Compani... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 10 2013]
Teva Announces First Patient Enrolled in Larges... [Published Business Wire Health News - Feb 05 2013]
TOPIN & ASSOCIATES SELECTS AN ACCOUNT SUPERVISO... [Published CisionWire - English - Dec 03 2012]
Fact Sheet for H. Lundbeck A/S [Published Able2Act - Mar 30 2009]
Fact Sheet for H. Lundbeck A/S [Published Able2Act - Jul 24 2008]
Fact Sheet for Teva Pharmaceutical Industries Ltd. [Published Able2Act - Apr 16 2008]